- Home
- ETON vs NRC Comparison
ETON vs NRC Comparison
Compare ETON & NRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- NRC
- Stock Information
- Founded
- ETON 2017
- NRC 1981
- Country
- ETON United States
- NRC United States
- Employees
- ETON N/A
- NRC N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- NRC Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ETON Health Care
- NRC Health Care
- Exchange
- ETON Nasdaq
- NRC Nasdaq
- Market Cap
- ETON 388.3M
- NRC 354.5M
- IPO Year
- ETON 2018
- NRC N/A
- Fundamental
- Price
- ETON $17.31
- NRC $14.65
- Analyst Decision
- ETON Strong Buy
- NRC
- Analyst Count
- ETON 3
- NRC 0
- Target Price
- ETON $29.67
- NRC N/A
- AVG Volume (30 Days)
- ETON 329.2K
- NRC 101.8K
- Earning Date
- ETON 08-07-2025
- NRC 10-24-2025
- Dividend Yield
- ETON N/A
- NRC 3.27%
- EPS Growth
- ETON N/A
- NRC N/A
- EPS
- ETON N/A
- NRC 0.77
- Revenue
- ETON $58,181,000.00
- NRC $140,314,000.00
- Revenue This Year
- ETON $105.25
- NRC N/A
- Revenue Next Year
- ETON $40.84
- NRC N/A
- P/E Ratio
- ETON N/A
- NRC $19.08
- Revenue Growth
- ETON 85.40
- NRC N/A
- 52 Week Low
- ETON $4.47
- NRC $9.76
- 52 Week High
- ETON $21.48
- NRC $22.99
- Technical
- Relative Strength Index (RSI)
- ETON 61.58
- NRC 47.80
- Support Level
- ETON $17.02
- NRC $14.45
- Resistance Level
- ETON $17.77
- NRC $15.60
- Average True Range (ATR)
- ETON 0.69
- NRC 0.64
- MACD
- ETON 0.03
- NRC -0.03
- Stochastic Oscillator
- ETON 78.80
- NRC 17.05
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.